Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)

Avalo Therapeutics (AVTX) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $1.4 million as the latest value for Q2 2019.

  • For the quarter ending Q2 2019, Asset Writedowns and Impairment fell 14.85% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2020, down 12.03%, and an annual FY2019 reading of $1.4 million, down 23.73% over the prior year.
  • Asset Writedowns and Impairment was $1.4 million for Q2 2019 at Avalo Therapeutics, up from $38438.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.7 million in Q2 2018 and bottomed at $38438.0 in Q4 2018.